Neurent Medical Raises €62.5 Million in Series C Financing

Neurent Medical has collected €62.5 million ($74 million) in an oversubscribed Series C financing round to drive its commercial expansion, broaden clinical evidence, and advance its product and indication pipeline.

MVM Partners led the financing, though other support came from Sofinnova Partners, and existing investors EQT Life Sciences, Atlantic Bridge, Fountain Healthcare Partners, and Enterprise Ireland.

“I am delighted to welcome MVM Partners and Sofinnova Partners to the Neurent Medical team, two global leaders in medtech investing,” Neurent Medical CEO Brian Shields said. “This Series C financing will support our commercial expansion and help bring NEUROMARK to the patients and physicians who need it most.”

Chronic rhinitis affects millions of people worldwide and is characterized by persistent symptoms including nasal congestion, rhinorrhea (runny nose), sneezing, and postnasal drip that can significantly diminish quality of life. The proprietary Impedance Controlled Radiofrequency technology incorporated into Neurent Medical’s flagship product, NEUROMARK, targets the overactive posterior nasal nerves (PNN) that drive these symptoms, providing clinicians with a differentiated and durable treatment option that addresses the root cause rather than merely managing symptoms.

“Our mission since inception has been to meaningfully improve patients’ lives while empowering ENT physicians with predictable, minimally invasive care,” Shields continued. “In addition to expanding patient access, this investment will also enable further evidence generation across broader populations and support the continued development of our exciting pipeline offerings.”

In connection with the funding round, Neurent Medical welcomed Kyle Dempsey, partner at MVM Partners; and Cedric Moreau, partner at Sofinnova Partners; to its Board of Directors.

“Millions of patients suffer from chronic rhinitis, and posterior nasal nerve ablation represents a powerful tool to provide proven relief,” Dempsey stated. “In this rapidly emerging category, Neurent has set a new standard with a best-in-class solution, powered by a proprietary impedance control system that delivers real-time feedback, giving clinicians greater treatment confidence, control, and predictability during every procedure.”

“Chronic rhinitis is a widespread and often overlooked condition affecting millions of patients with limited effective treatment options. Neurent Medical has developed a truly differentiated approach supported by a growing body of clinical evidence demonstrating meaningful and durable patient benefit,” Moreau added. We also see significant potential to expand this platform into additional indications, and we are confident in our partnership with Neurent Medical at this pivotal stage of commercial growth.”

Neurent Medical is striving to transform the treatment landscape for chronic inflammatory sinonasal diseases. Its flagship NEUROMARK System uses proprietary Impedance Controlled Radiofrequency technology to gently disrupt hyperactive posterior nasal nerves, delivering durable symptom relief from chronic rhinitis with minimal downtime and a strong safety profile. Headquartered in Galway, Ireland, with U.S. operations in Braintree, Mass., Neurent is advancing both scientific evidence and clinical adoption to establish a new standard of care in chronic rhinitis management.

MVM has invested in high-growth healthcare businesses since 1997. With teams in Boston, London, and the San Francisco Bay Area, MVM has a global investment outlook spanning medical technology, pharmaceuticals, diagnostics, contract research and manufacturing, digital health, and other sectors of healthcare.

Sofinnova Partners is a European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London, and Milan, the firm is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. Founded in 1972, Sofinnova Partners has backed more than 500 companies and created market leaders worldwide. Sofinnova Partners currently manages more than €4 billion in assets.